The Filing Desk

Assembly Biosciences vs Kura Oncology

Assembly Biosciences ASMB · Kura Oncology KURA · Pharmaceuticals

Assembly Biosciences reported revenue of $72 million in fiscal 2025, about the same as Kura Oncology's $68 million in fiscal 2025. Assembly Biosciences' revenue grew 153.5% in its latest year, and Kura Oncology's grew 25.2%. Assembly Biosciences had an operating margin of -16.8%, against -449.9% at Kura Oncology. Free cash flow was −$41 million at Assembly Biosciences and −$71 million at Kura Oncology.

Side by side

Assembly BiosciencesKura Oncology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$72M$68M
Revenue growth153.5%25.2%
Revenue growth a year, last 5 years−1.8%—
Gross margin——
Operating margin−16.8%−449.9%
Net margin−8.5%−412.9%
Free cash flow−$41M−$71M
Free cash flow margin−56.9%−104.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count86.7%1.8%
Last close$22.50$7.35
P/E at the last close——
Insider trades, last 12 monthssold $14,687bought $3.9 million, sold $4.0 million
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Assembly BiosciencesKura Oncology
Operating margin
Percent of revenue
Assembly BiosciencesKura Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Assembly BiosciencesKura Oncology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Assembly Biosciences and Kura Oncology pages.